Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.51 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 3/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 3/20 | 0.50 |
| ▸ | SMO | Q99835 | 2/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.48 |
| ▸ | WNT3A | P56704 | 2/20 | 0.48 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400789 | 0.81 | SMARCA2 (0.68) | CNR1SMARCA2SMARCA4 | |
| SCHEMBL12788367 | 0.80 | CYP17A1 (0.57) | PORCNSMARCA2SMARCA4 | |
| SCHEMBL16371069 | 0.77 | PIK3C3 (0.59) | CNR1 | |
| SCHEMBL4516268 | 0.77 | ROCK2 (0.57) | — | |
| SCHEMBL28386018 | 0.76 | SMN1; SMN2 (0.61) | — | |
| SCHEMBL1137060 | 0.76 | SMARCA2 (0.46) | CNR1SMARCA2SMARCA4PSEN1PSEN2 | |
| SCHEMBL25070215 | 0.75 | ADORA2A (0.54) | CNR1SMOCCNCCDK8 | |
| SCHEMBL31301463 | 0.74 | MET (0.62) | CNR1SMOCCNCCDK8 | |
| SCHEMBL4027001 | 0.74 | IDO1 (0.55) | CCNCCDK8KMO | |
| SCHEMBL2182426 | 0.74 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473501-B1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-9725433-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170066738-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. | 2017-03-09 | — | — | US | disclosed |
| WO-2015069287-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8906944-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8614234-B2 | Compounds as tyrosine kinase modulators | ALLERGAN, INC. (US) | 2013-12-24 | — | — | US | disclosed |
| US-20130065880-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-2473501-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | Allergan, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065880-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | CNR1 1406/4885PORCN 4515/4885SMARCA2 4556/4885 |
| US-20110053905-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | CNR1 1406/4885PORCN 4515/4885SMARCA2 4556/4885 |
| US-20170066738-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ABL1, ERBB2, LCK | CNR1 1406/4885PORCN 4515/4885SMARCA2 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.